Cavit Boz

Trabzon, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 150 publications

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Journal: Multiple sclerosis and related disorders

Published: April 10, 2026

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Journal: Brain : a journal of neurology

Published: March 12, 2026

Beyond serology: clinical and prognostic determinants in patients with dual AQP4-IgG and MOG-IgG seropositivity.

Beyond serology: clinical and prognostic determinants in patients with dual AQP4-IgG and MOG-IgG seropositivity.

Journal: Multiple sclerosis and related disorders

Published: March 12, 2026

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder.

Journal: Neurology

Published: March 05, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Managing reactivation of multiple sclerosis during treatment with natalizumab.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: December 20, 2025

Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.

Real-world effectiveness and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.

Journal: Journal of neurology

Published: November 04, 2025

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal: Journal of neurology

Published: November 01, 2025

Disease course after pregnancy in women with progressive multiple sclerosis symptoms.

Disease course after pregnancy in women with progressive multiple sclerosis symptoms.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 20, 2025

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Journal: CNS drugs

Published: September 04, 2025

Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study.

Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study.

Journal: Multiple sclerosis and related disorders

Published: August 27, 2025

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 07, 2025

Showing 1-12 of 150

Last Updated: 09/26/2026